About Us
Founded in 2018 in the heart of Texas along the Temple-Austin biotechnology corridor, Artemis Biotechnologies was created to bring to market several drugs which show promise in the treatment of preeclampsia and ovarian cancer. Our scientists have professional backgrounds in the areas of Medicinal Chemistry and Drug Development, Synthetic Organic and Medicinal Chemistry, Biochemistry, Molecular & Cellular Biology, Preclinical Drug Development, and Higher Education experience.
Mission
Artemis Biotechnologies is an organization carrying out basic, preclinical, and translational research to deliver improved diagnostics and therapeutics for human disease. Projects originate from in-house research or by collaboration or license from outside of Artemis Biotechnologies. As projects mature, they may be commercialized through out-licensing to commercial entities.
Experience
Dr. Uddin’s research focuses on translational research in maternal/fetal medicine. HIs research currently focuses on two diseases of high unmet medical need: preeclampsia (hypertension during pregnancy) and gynecologic cancer, with a focus on ovarian cancer. A major long-term goal of his lab is to determine the pathogenesis and molecular signaling in preeclampsia. He worked as part of the team that developed a first-generation ELISA for MBG in plasma and urine and recently worked with Mr. Wages to set up an improved version of this assay. In addition, his work has identified several novel compounds for the treatment of ovarian cancer. These are being studied to understand their mechanism of action and to advance them through a series of preclinical evaluations.